hippo pathway

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year
Endpoints
Wed, 12/16/20 - 12:38 pm
Vivace Therapeutics
oncology
hippo pathway
funding